Table 2.
Sociodemographic and clinical characteristics of included patients (n = 224).
| Characteristics | All Patients (n = 224) | No IFI (n = 198) |
IFI (n = 26) |
p-Value | Missing Data (n/Total) | |
|---|---|---|---|---|---|---|
| Age (years) | 57.2 ± 11.1 | 58.0 ± 10.5 | 51.8 ± 13.9 | 0.038 | 0/224 | |
| Male sex | 172 (76.8) | 154 (77.8) | 18 (69.2) | 0.459 | 0/224 | |
| Weight (kg) | 81.5 ± 16.4 | 81.7 ± 16.0 | 80.2 ± 19.8 | 0.680 | 0/224 | |
| Height (cm) | 174.4 ± 8.5 | 174.3 ± 8.4 | 175.5 ± 8.9 | 0.480 | 0/224 | |
| Body mass index (kg/m2) | 26.8 ± 5.0 | 26.9 ± 4.9 | 25.9 ± 5.7 | 0.343 | 0/224 | |
| SAPS III score | 45.0 ± 8.5 | 44.9 ± 8.6 | 45.8 ± 8.3 | 0.635 | 7/224 | |
| MELD score | 14 (6–40) | 14 (6–40) | 16 (6–40) | 0.174 | 7/224 | |
| Charlson comorbidity index | 4 (0–12) | 4 (0–12) | 4 (0–9) | 0.672 | 2/224 | |
| Underlying disease | 0.198 | 0/224 | ||||
| Alcoholic liver disease | 56 (25.0) | 50 (25.3) | 6 (23.1) | 1.000 | 0/224 | |
| Malignancy and other tumors | 92 (41.1) | 83 (41.9) | 9 (34.6) | 0.531 | 0/224 | |
| Hepatocellular carcinoma | 85 (92.4) | 76 (91.6) | 9 (100.0) | 0.710 | ||
| Cholangiocellular carcinoma | 3 (3.3) | 3 (3.6) | 0 (0.0) | 0.528 | ||
| Neuroendocrine tumor | 3 (3.3) | 3 (3.6) | 0 (0.0) | 0.528 | ||
| Polycystic liver disease | 1 (1.1) | 1 (1.2) | 0 (0.0) | 0.716 | ||
| Virus related | 9 (4.0) | 8 (4.0) | 1 (3.8) | 1.000 | 0/224 | |
| Non-alcoholic fatty liver disease | 14 (6.3) | 14 (7.1) | 0 (0.0) | 0.380 | 0/224 | |
| Budd-Chiari syndrome | 6 (2.7) | 6 (3.0) | 0 (0.0) | 1.000 | 0/224 | |
| Acute liver failure | 10 (4.5) | 7 (3.5) | 3 (11.5) | 0.096 | 0/224 | |
| Cholestatic | 17 (7.6) | 14 (7.1) | 3 (11.5) | 0.426 | 0/224 | |
| Autoimmune hepatitis | 8 (3.6) | 6 (3.0) | 2 (7.7) | 0.234 | 0/224 | |
| Metabolic Liver Disease | 10 (4.5) | 9 (4.5) | 1 (3.8) | 1.000 | 0/224 | |
| Other | 2 (0.9) | 1 (0.5) | 1 (3.8) | 0.219 | 0/224 | |
Abbreviations: SAPS III: simplified acute physiology score III; MELD: model of end-stage liver disease.